Frequency of Appropriate Use of Pancreatic Enzyme Replacement Therapy and Symptomatic Response in Pancreatic Cancer Patients.
Adult
Aged
Aged, 80 and over
Enzyme Replacement Therapy
/ methods
Exocrine Pancreatic Insufficiency
/ complications
Female
Humans
Male
Middle Aged
Pancreas
/ drug effects
Pancreatic Neoplasms
/ complications
Pancrelipase
/ administration & dosage
Retrospective Studies
Surveys and Questionnaires
Treatment Outcome
Young Adult
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
07 2019
07 2019
Historique:
entrez:
19
6
2019
pubmed:
19
6
2019
medline:
3
3
2020
Statut:
ppublish
Résumé
Pancreatic cancer (PC) and its treatments can result in pancreatic exocrine insufficiency that requires pancreatic enzyme replacement therapy (PERT). Appropriate PERT usage is during meals and snacks. The aim was to determine the frequency of appropriate use of PERT and its impact on symptom alleviation in PC through a patient-reported outcomes online platform. Users in the Pancreatic Cancer Action Network's Patient Registry were prompted to answer a standalone questionnaire about their experience with PERT. Two hundred sixty-two users completed the PERT questionnaire (January 2016-January 2018). Patients who reported taking PERT with meals had higher alleviation of symptoms compared with those taking PERT prior to or after meals. Specifically, "feeling of indigestion," "light-colored or orange stools," and "visible food particles in stool" were significantly decreased. Patients taking PERT with meals reported weight gain and less weight loss. Of the 89% of PC patients prescribed PERT, 65% were prescribed PERT appropriately with all meals and snacks. Overall compliance with PERT administration guidelines was low (50% [105/208]). Improvement in symptoms significantly correlated with appropriate use of PERT. Increase in PC patient and provider education about appropriate PERT usage and administration is warranted.
Identifiants
pubmed: 31210656
doi: 10.1097/MPA.0000000000001330
pii: 00006676-201907000-00005
pmc: PMC6749961
doi:
Substances chimiques
Pancrelipase
53608-75-6
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
780-786Références
Cancer. 1996 Aug 1;78(3 Suppl):615-26
pubmed: 8681300
Pancreas. 2017 Mar;46(3):341-346
pubmed: 28099252
Aliment Pharmacol Ther. 2011 May;33(10):1152-61
pubmed: 21418260
Am Fam Physician. 2006 Feb 1;73(3):485-92
pubmed: 16477897
Ann Oncol. 1999;10 Suppl 4:140-2
pubmed: 10436807
Ann Surg. 2002 Sep;236(3):355-66; discussion 366-8
pubmed: 12192322
Int J Clin Pract. 2018 Feb;72(2):
pubmed: 29405509
HPB (Oxford). 2017 Oct;19(10):859-867
pubmed: 28711377
Am J Gastroenterol. 2010 Oct;105(10):2276-86
pubmed: 20502447
Aliment Pharmacol Ther. 2005 Apr 15;21(8):993-1000
pubmed: 15813835
Gut. 1998 Jan;42(1):92-6
pubmed: 9505892
Dig Liver Dis. 2012 Nov;44(11):945-51
pubmed: 22749648
Gut. 2017 Aug;66(8):1354-1355
pubmed: 27941156
Oncologist. 2019 May;24(5):691-701
pubmed: 30591550
Cancer. 1982 Nov 15;50(10):2189-92
pubmed: 7127259
CA Cancer J Clin. 2018 Jan;68(1):7-30
pubmed: 29313949
Dig Liver Dis. 2015 Dec;47(12):1013-20
pubmed: 26211872
JOP. 2007 Jan 09;8(1 Suppl):132-40
pubmed: 17228145
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Pancreatology. 2011;11(6):535-45
pubmed: 22094930
Support Care Cancer. 2017 Jun;25(6):1963-1971
pubmed: 28161789
Pancreas. 2021 Feb 1;50(2):176-182
pubmed: 33560089
Pancreas. 2006 Aug;33(2):156-62
pubmed: 16868481